On May 16, 2025, Wedbush analyst Laura Chico reiterated her "Outperform" rating for Gossamer Bio (GOSS, Financial), maintaining the price target at $4.00 USD. The rating and price target remain unchanged from the previous assessment.
Gossamer Bio (GOSS, Financial), traded on NASDAQ, continues to receive confidence from analysts, as reflected in the consistent price target set by Wedbush. The price target maintained at $4.00 USD indicates the analyst's steady outlook on the company's stock performance.
The reiteration by Wedbush comes as part of their ongoing coverage of Gossamer Bio (GOSS, Financial), ensuring investors are informed of the unchanged outlook amidst market movements. This affirmation of the "Outperform" rating suggests that Gossamer Bio (GOSS) is expected to perform better than the overall market in the near future.
Wall Street Analysts Forecast
Based on the one-year price targets offered by 7 analysts, the average target price for Gossamer Bio Inc (GOSS, Financial) is $7.61 with a high estimate of $15.00 and a low estimate of $1.25. The average target implies an upside of 607.64% from the current price of $1.08. More detailed estimate data can be found on the Gossamer Bio Inc (GOSS) Forecast page.
Based on the consensus recommendation from 9 brokerage firms, Gossamer Bio Inc's (GOSS, Financial) average brokerage recommendation is currently 1.9, indicating "Outperform" status. The rating scale ranges from 1 to 5, where 1 signifies Strong Buy, and 5 denotes Sell.
